Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report

Atezolizumab is a monoclonal antibody immune checkpoint inhibitor that binds to programmed death ligand 1 to selectively prevent its interaction with programmed cell death-1 (PD-1) and B7.1 (CD80) receptors. We present a case of a 61-year-old man with metastatic urothelial carcinoma of the right ureter and urinary bladder. After gemcitabine/cisplatin as the first-line chemotherapy and surgery, the patient received atezolizumab 1200 mg i.v. q3w. Following the first atezolizumab administration, he noted vitiligo periorally, on his hands, legs, and the scalp. The patient’s overall survival (OS) of >26 months and continuing response to atezolizumab treatment is considerably better than median OS in the SAUL study of 8.7 months (IM-vigor211-like patients’ OS 10.0 months). This case indicates that increased efficacy of atezolizumab can be associated with cutaneous immune related adverse events, reflecting the known Th17 polarization of these diseases and showing that individuals with cutaneous adverse events could benefit from PD-1 checkpoint blockade in the therapy of metastatic urothelial carcinoma.
Atezolizumab is a humanized monoclonal antibody that prevents the binding of programmed death ligand 1 (PD-L1) to the programmed cell death-1 (PD-1) and B7.1 (also known as CD80) receptor. PD-L1, a transmembrane protein expressed on tumor cells, upon binding to PD-1 and CD80 reduces anti-tumor T-cell activity (1). Atezolizumab is prescribed for the therapy of triple negative, metastatic, or locally advanced breast cancer, extensive stage small cell lung cancer, non-small cell lung cancer, and urothelial carcinoma that has progressed during or after a prior platinum-based chemotherapy (2-6).

CASE REPORT

A 61-year-old, well developed, well nourished, white male, who smoked a pack daily for 45 years but was otherwise healthy, was admitted to our department in June 2015 for recurrent hematuria, requiring transurethral resection of the urinary bladder, which revealed a urothelial papillary carcinoma G2. Multi-slice computed tomography (MSCT) scan in July 2015 demonstrated bilateral ureterovesical junction infiltration by the tumor, with right hydronephrosis and multiple pulmonary metastases (Table 1). Due to a deteriorating renal function (creatinine 564 µmol/L, blood urea nitrogen [BUN] 22.3 mmol/L), in September 2015 a right sided “JJ” catheter was placed, which led to an improvement in kidney function (creatinine 153 µmol/L, BUN 9 mmol/L). The patient had Eastern Cooperative Oncology Group (ECOG) performance status 0. From October 2015 to April 2016, six cycles of gemcitabine/cisplatin chemotherapy were administered, with a MSCT scan reevaluation after three months showing a regression of pulmonary metastases and a control MSCT scan after chemotherapy showing stable disease.

In June 2016, the patient underwent radical cystectomy with pelvic lymphadenectomy, left ureterocutaneous anastomosis, and right nephrectomy. Pathohistology re-

TABLE 1. Patient care timeline

| Time                | Event                                                                 |
|---------------------|----------------------------------------------------------------------|
| June 2015           | Urothelial papillary carcinoma G2 diagnosed                          |
| July 2015           | Right hydronephrosis with multiple pulmonary metastases diagnosed    |
| September 2015      | Right sided “JJ” catheter placement                                  |
| October 2015 to April 2016 | Six cycles of gemcitabine/cisplatin chemotherapy                     |
| June 2016           | Radical cystectomy, pelvic lymphadenectomy, left ureterocutaneous anastomosis, and right nephrectomy |
| June 2016           | Pathohistology: urothelial carcinoma of the right ureter G2 pT2 N0 and urothelial carcinoma of the urinary bladder G2 pT1 N0 |
| February 2017       | Pulmonary disease progression                                         |
| April 2017          | SAUL study enrolment                                                 |
| May 2017            | First atezolizumab (Tecentriq®)1200 mg i.v. q3w applied               |
| May 2017            | Development of vitiligo periorally, on hands, legs, and the scalp    |
| July 2018           | Right temporal region lipoma removal                                  |
| February 2019       | Stereotactic body radiation therapy of 55 Gy for a solitary pulmonary metastasis |
| April 2019          | The 32nd atezolizumab (Tecentriq®) cycle                             |
revealed two tumors: urothelial carcinoma of the right ureter, G2 pT2 N0, and urothelial carcinoma of the urinary bladder, G2 pT1 N0, measuring 1 × 2 cm and 11 × 9 cm, respectively (pN = 0/16, R0). In February 2017, pulmonary disease progression was noted. In April 2017, he was enrolled into the SAUL study and in May 2017 first received atezolizumab (Tecentriq®; Hoffmann-La Roche AG, Basel, Switzerland) 1200 mg i.v. q3w (7). Over the following 3 months, the two metastatic pulmonary lesions were considerably reduced in size, from 21 and 14 mm to 7 and 4 mm, respectively. Following the first atezolizumab administration in May 2017, the patient noted vitiligo periorally, on his hands (Figure 1), legs (Figure 2), and the scalp. He also experienced G2 fatigue and transient hypothyroidism. In July 2018, he noted a soft-tissue growth in the right temporal region, which was pathologically confirmed to be a lipoma.

Control MSCT scan in February 2019 showed that a solitary pulmonary metastasis grew from 7 to 15.25 mm, which is why stereotactic body radiation therapy of 55 Gy was applied. In April 2019, the 32nd atezolizumab cycle was administered. Now, 45 months after the diagnosis, the patient is 65 years old, with ECOG = 0. He responded to the first-line treatment with gemcitabine and cisplatin, which lasted for 16 months. His response to second-line atezolizumab therapy, with concomitant development of vitiligo as an immune related adverse event (irAE), still continues after 26 months of treatment.

**DISCUSSION**

A few smaller clinical studies suggested that dermatological immune related adverse events following the administration of checkpoint inhibitors can be associated with treatment efficacy (8). Khan et al demonstrated that patients who experienced low-grade dermatological irAEs had longer OS in IMvigor211 (P = 0.024; hazard ratio [HR] 0.66; 95% confidence interval [CI] 0.45-0.95) and IMvigor210 (P = 0.0023; HR 0.53; 95% CI 0.35-0.80) trials (9). In their analysis, polygenic risk for psoriasis was associated with an increased odds of skin irAEs (P = 0.002; OR 1.79; 95% CI 1.24-2.40), while high polygenic risks for vitiligo (P = 0.0016; HR 0.58; 95% CI 0.41-0.81) and psoriasis (P = 5.5 × 10−5; HR 0.50; 95% CI 0.36-0.70), as well as low for atopic dermatitis (P = 0.0008; HR 0.57; 95% CI 0.41-0.79) were associated with longer OS under anti-PD-L1 atezolizumab monotherapy in comparison with chemotherapy (9).

Our patient’s OS of >23 months on atezolizumab in the second-line therapy is considerably higher than the median OS in the SAUL study of 8.7 months (IMvigor211-like patients OS 10.0 months) and, in our opinion, it highlights that concomitant skin autoimmunity can be associated with increased efficacy of atezolizumab in the treatment of metastatic urothelial carcinoma (7,10).

In conclusion, a positive association between overall survival and skin irAEs (vitiligo and psoriasis) reflects the known Th17 polarization of these diseases, indicating that individuals with high Th17 polarization benefit from PD-1 checkpoint blockade in the therapy of metastatic urothelial carcinoma. Genetic background and tumor factors likely interact and affect survival benefit associated with checkpoint blockade as compared with chemotherapy. Median OS in the second-line with classical chemotherapy for metastatic urothelial carcinoma is 6-9 months (10). Our patient remains asymptomatic with ECOG = 0 and an ongoing response to atezolizumab therapy for more than 26 months.

**Funding** None.

**Ethical approval** procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees. The patient provided informed consent for the publication of data and images.

**Declaration of authorship** MB, MiG, and MaG conceived and designed the study, all authors acquired the data, all authors analyzed and interpreted the data, DR, MB, and RL drafted the manuscript, RL, MiG, and MaG critically
revised the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests RL: speaker/advisory board fees for Astellas, Roche, Sandoz, MSD; MaG: speaker/advisory board fees for BMS, Pfizer, Novartis, Astellas, Sanofi, Janssen, Roche, Sandoz, Amgen, Bayer, Pharmacia, MSD; Alvogen; non-financial support for drugs (BMS, Roche, Janssen); MiG: speaker fees for Pfizer, Novartis, Astellas, Sanofi, Janssen, Roche. MB: speaker fees for Novartis, Roche, Sandoz. RL is an Editorial Board member of the Croatian Medical Journal. To ensure that any possible conflict of interest relevant to the journal has been addressed, this article was reviewed according to best practice guidelines of international editorial organizations. All other authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 Blair HA. Atezolizumab: A review in previously treated advanced non-small cell lung cancer. Target Oncol. 2018;13:399-407. Medline:29783577 doi:10.1007/s11523-018-0570-5
2 Kwiatkowska D, Kluska P, Reich A. Beyond PD-1 immunotherapy in malignant melanoma. Dermatol Ther (Heidelb). 2019;9:243-57. Medline:30927248 doi:10.1007/s13555-019-0292-3
3 Lorenz J. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. Geburtshilfe Frauenheilkd. 2019;79:232. doi:10.1055/a-0832-5840
4 Horn L, Mansfield AS, Szczesna A, Havel L, Krazkowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-9. Medline:30280641 doi:10.1056/NEJMoa1809064
5 Pacheco JM, Camidge DR, Doebele RC, Schen K. A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer. Front Oncol. 2019;9:195. Medline:30984621 doi:10.3389/fonc.2019.00195
6 Rui X, Gu TT, Pan HF, Zhang HZ. Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis. Int Immunopharmacol. 2019;67:378-85. Medline:30584967 doi:10.1016/j.intimp.2018.12.018
7 Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, et al. Primary results from SAU1, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol. 2019;76:73-81. Medline:30910346 doi:10.1016/j.eururo.2019.03.015
8 Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-68. Medline:29320654 doi:10.1056/NEJMra1703481
9 Khan Z, Di Nucci F, Kwan A, Christian H, Sanjeev M, Vincent R, et al. genetic risk for skin autoimmunity impacts the safety and efficacy of immune checkpoint blockade in urothelial carcinoma. FOCS 2019 congress; Poster presentation W99; Boston, 2019, USA.
10 Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748-57. Medline:29268948 doi:10.1016/S0140-6736(17)33297-X